Suven Life Sciences gets Four new patents for a molecule

These patents are the sole propriety of Suven Life Sciences and have been discovered after a thorough internal research and medical investigation. These patents are valid up to 2031, with the small exception of South Africa extending the validity till 2030. Now, Suven has a total of 16 granted patents from China, 19 from Mexico and 22 from South Africa.

As reported by PTI,

In a BSE filing, the company said that it "secured patents from China and South Africa to the new chemical entities (NCE) for central nervous system (CNS) therapy".

It further said: "Suven also secured a patent for their NCE in Mexico and the granted claims of this patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder and the patent is valid through 2030."

"Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II," Suven said.

Shares of Suven Life Sciences soared in its day trade on BSE.